Tuğba Falay Gür

Tuğba Falay Gür

Auto-generated profile, based on publicly available information

Tuğba Falay Gür

Department of Dermatology University of Health Sciences Sultan 2. Abdulhamid Han Training and Research Hospital Istanbul Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2018 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
TGTuğba Falay Gur
Tuğba Falay Gur
AEAslı Vefa Erdemir
Aslı Vefa Erdemir
MGMehmet Salih Gurel
Mehmet Salih Gurel
AKAbdurrahim Kocyigit
Abdurrahim Kocyigit
EGEray Metin Guler
Eray Metin Guler
DEDuygu Erdil
Duygu Erdil

21 October 2020 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
SESevil Savaş Erdoğan
Sevil Savaş Erdoğan
TGTuğba Falay Gür
Tuğba Falay Gür
BDBilal Doğan
Bilal Doğan

24 August 2021 in Postgraduate Medicine
Verified
Journal Article
Closed access
SESevil Savaş Erdoğan
Sevil Savaş Erdoğan
TGTuğba Falay Gür
Tuğba Falay Gür
BDBilal Doğan
Bilal Doğan
Effective use of technology can provide advantages for both patients and physicians in skin biopsy practice. We aimed to investigate the effects of video-based information on the anxiety, pain and satisfaction levels of patients undergoing biopsy. Patients were randomized and divided into two groups as video-informed and verbally informed. The anxiety levels were evaluated using the State-Trait Anxiety Inventory (STAI) and measuring the physiological parameters, systolic and diastolic blood pressure, heart rate, and respiratory rate. After the informing process, the STAI’s state form was reevaluated, and physiological parameters were measured again. After the biopsy, the level of pain was evaluated using the visual analog scale (VAS), and patient satisfaction was assessed with the satisfaction scale. Fifty-two in the video-informed group and 50 in the verbally informed group completed the study. Compared to the baseline values, the STAI and STAI-state scores, systolic blood pressure, heart rate and respiratory rate of the patients in the video-informed group decreased (p < 0.0001, p < 0.0001, p = 0.003, p = 0.007, and p < 0.0001, respectively), and the systolic blood pressure, diastolic blood pressure, heart rate and respiratory rate values decreased in the verbally informed group (p < 0.0001, p = 0.014, p = 0.005, and p < 0.0001, respectively). According to VAS, 98.1% of the patients in the video-informed group and 86% of those in the verbally informed group described no or mild pain, and pain levels were lower in the video-informed group (p = 0.030). Video-based information prior to skin biopsy may be more useful in managing anxiety and pain in patients than traditional verbal information.

14 April 2020 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
SESevil Savas Erdogan
Sevil Savas Erdogan
TGTugba Falay Gur
Tugba Falay Gur
AEAslı Vefa Turgut Erdemir
Aslı Vefa Turgut Erdemir
BDBilal Dogan
Bilal Dogan

2 July 2021 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
TGTuğba Falay Gür
Tuğba Falay Gür
SESevil Savaş Erdogan
Sevil Savaş Erdogan
BDBilal Doğan
Bilal Doğan

14 September 2020 in Cutaneous and Ocular Toxicology
Verified
Journal Article
Closed access
TGTugba Falay Gur
Tugba Falay Gur
SESevil Savas Erdogan
Sevil Savas Erdogan
VEVefa Aslı Erdemir
Vefa Aslı Erdemir
BDBilal Doğan
Bilal Doğan
Purpose: In some diabetic patients receiving omalizumab therapy, blood glucose regulation is impaired. However, the effect of omalizumab on glucose homeostasis in non-diabetic patients remains unknown. Methods: The patients were given subcutaneous omalizumab at a dose of 300 mg every four weeks for the treatment of chronic urticaria in the present study. Fasting blood glucose, fasting plasma insulin, total cholesterol, triglyceride, high-density (HDL) and low-density lipoprotein (LDL) were studied before and at the 12th week of treatment. The homeostatic model assessment for insulin resistance (HOMA-IR) was used to determine insulin resistance. Results: Forty of the 45 patients included in the study completed 12 weeks of treatment. While fasting blood glucoses (p = 0.011) and HOMA-IR values (p = 0.027) were significantly increased in the 12th week, the increase in fasting insulin level was not significant (p = 0.07). After treatment, 10 patients developed impaired fasting glucose and 13 developed insulin resistance. Conclusion: The increase in blood glucose levels may be associated with the paradoxically increase of histamine levels in the blood by omalizumab. If this increase cannot be balanced with insulin, patients may develop impaired glucose tolerance and insulin resistance. Therefore, we suggest that patients using omalizumab should be followed up for glucose homeostasis and insulin resistance.